Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
A once-weekly combo of semaglutide and basal insulin icodec (IcoSema) beat daily insulin glargine in a phase 3b trial, delivering better A1c reductions, weight loss, and less hypoglycemia in insulin-naive adults with type 2 diabetes. The COMBINE 4 trial enrolled 485 participants over 40 weeks, with IcoSema showing clear superiority on all key endpoints. The drug is approved in the EU and several other countries but hasn't yet been filed for US approval.
A once-weekly fixed-dose combination of semaglutide and basal insulin icodec — branded IcoSema (Novo Nordisk) — significantly outperformed once-daily insulin glargine U100 in adults with type 2 diabetes (T2D) who were naive to both insulin and GLP-1 receptor agonists, according to results from the COMBINE 4 phase 3b trial published in The Lancet Diabetes & Endocrinology.
The 40-week, multinational, randomized trial enrolled 485 participants, with more than 90% completing the treatment period. IcoSema demonstrated superiority across all three key endpoints: glycemic control, body weight, and hypoglycemia risk — addressing the most common concerns clinicians face when intensifying insulin therapy.
By the Numbers:
Why it matters: IcoSema offers a promising once-weekly alternative to daily basal insulin, potentially reducing injection burden while improving outcomes. Though approved in the EU, China, Japan, and South Korea, Novo Nordisk has not yet filed for US approval — leaving American patients waiting on a therapy that could meaningfully change how T2D is managed after oral medications fall short.
